Professional Documents
Culture Documents
Excluding patients with acute renal failure and/or vancomycin exposure within 7 days prior to the first dose of study medication.
Kruskall-Wallis.
Barriere et al. BMC Infectious Diseases 2014, 14:183 Page 4 of 5
http://www.biomedcentral.com/1471-2334/14/183
and has received grants/grants pending from Duke University (NIH) and
Theravance. GRC has served on advisory boards for Cempra, Cerexa, Inimex,
Pfizer, and Trius; is a consultant for Astellas, Cempra, Cerexa, Dr Reddys Lab,
Inimex, Merck, Pfizer, Polymedix, PRA International, Theravance, and Trius; has
received grants/grants pending from Cubist, Innocoll, The Medicines Company,
and Theravance; and has received other financial support (e.g., travel expenses,
manuscript preparation reimbursement) from Theravance. ER has served as a
consultant/on advisory boards for Astellas, Atox, Bayer, BiondVax, Merck, Ortho-
McNeil, Pfizer, Theravance, and Wyeth; has provided expert testimony for
Johnson & Johnson; has received grants/other research support from Astellas,
Bayer-Schering, Cubist, Daiichi, Merck, Pfizer, Theravance, and Wyeth; and has
received payment for lectures/speakers bureaus from Astellas, Bayer, Cubist, and
Pfizer.
Authors contributions
SLB was the ATTAIN study monitor, was involved in the study design and
data interpretation, and was the lead author of this manuscript. FCG was
involved in the statistical analysis, data interpretation, and development of
the manuscript. MES was an ATTAIN study investigator, and was involved in
data interpretation and development of the manuscript. GRC was an ATTAIN
study co-principal investigator, and was involved in the study design, data
interpretation, and development of the manuscript. ER was an ATTAIN study
co-principal investigator, and was involved in the study design, data interpret-
ation, and development of the manuscript. All authors reviewed and approved
the final version of the manuscript.
Author information
Fredric C. Genter was an employee of Theravance, Inc. at the time of the study.
Acknowledgments
The ATTAIN studies and publication development were supported by
Theravance, Inc. The authors would like to acknowledge Whedy Wang
(Theravance, Inc.) for statistical support and advice. Editorial and writing
support was provided by Emily Howard, a medical writer at Envision
Scientific Solutions, funded by Theravance.
Author details
1
Theravance, Inc., South San Francisco, CA 94080, USA.
2
Centro de Educacin
Mdica e Investigaciones Clinicas (CEMIC) Norberto Quirno, Buenos Aires,
Argentina.
3
Duke Clinical Research Institute and Department of Medicine,
Division of Infectious Diseases, Duke University Medical Center, Durham, NC
27710, USA.
4
Section of Infectious Diseases, Department of Internal Medicine
and Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Received: 24 June 2013 Accepted: 31 March 2014
Published: 4 April 2014
References
1. DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS: Epidemiology, treatment,
and outcomes of nosocomial bacteremic Staphylococcus aureus
pneumonia. Chest 2005, 128(3):14141422.
2. American Thoracic Society; Infectious Diseases Society of America:
Guidelines for the management of adults with hospital-acquired,
ventilator-associated, and healthcare-associated pneumonia. Am J Respir
Crit Care Med 2005, 171(4):388416.
3. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M,
Dalovisio JR, Levine DP: Vancomycin therapeutic guidelines: a summary
of consensus recommendations from the Infectious Diseases Society of
America, the American Society of Health-System Pharmacists, and the
Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009,
49(3):325327.
4. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST,
Kollef MH: Predictors of mortality for methicillin-resistant Staphylococcus
aureus health-care-associated pneumonia: specific evaluation of
vancomycin pharmacokinetic indices. Chest 2006, 130(4):947955.
5. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME:
Clinical outcomes and nephrotoxicity associated with vancomycin trough
concentrations during treatment of deep-seated infections. Expert Opin
Drug Saf 2010, 9(1):914.
6. Kunkel M, Chastre JE, Kollef MH, Niederman MS, Shorr AF, Wunderink RG,
McGee W, Olvey S, Reisman A, Baruch A: Linezolid vs vancomycin in the
treatment of nosocomial pneumonia proven due to methicillin-resistant
Staphylococcus aureus (abstract LB-49), Infectious Diseases Society of
America (IDSA) 48th Annual Meeting. Canada: Vancouver, BC; 2010.
7. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH: A retrospective
analysis of possible renal toxicity associated with vancomycin in patients
with health care-associated methicillin-resistant Staphylococcus aureus
pneumonia. Clin Ther 2007, 29(6):11071115.
8. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL: Relationship
between initial vancomycin concentration-time profile and nephrotoxicity
among hospitalized patients. Clin Infect Dis 2009, 49(4):507514.
9. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP:
Vancomycin: we can't get there from here. Clin Infect Dis 2011,
52(8):969974.
10. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G,
Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY,
Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME; for the
ATTAIN Study Group: Telavancin versus vancomycin for hospital-acquired
pneumonia due to gram-positive pathogens. Clin Infect Dis 2011,
52(1):3140.
11. Wong-Beringer A, Joo J, Tse E, Beringer P: Vancomycin-associated
nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J
Antimicrob Agents 2011, 37(2):95101.
12. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD:
Relationship between vancomycin trough concentrations and nephrotoxicity:
a prospective multicenter trial. Antimicrob Agents Chemother 2011,
55(12):54755479.
13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vanco-
mycin therapy for methicillin-resistant Staphylococcus aureus infections:
efficacy and toxicity. Arch Intern Med 2006, 166(19):21382144.
doi:10.1186/1471-2334-14-183
Cite this article as: Barriere et al.: Effect of vancomycin serum trough
levels on outcomes in patients with nosocomial pneumonia due to
Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of
the Phase 3 ATTAIN studies. BMC Infectious Diseases 2014 14:183.
Submit your next manuscript to BioMed Central
and take full advantage of:
Convenient online submission
Thorough peer review
No space constraints or color gure charges
Immediate publication on acceptance
Inclusion in PubMed, CAS, Scopus and Google Scholar
Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit
Barriere et al. BMC Infectious Diseases 2014, 14:183 Page 5 of 5
http://www.biomedcentral.com/1471-2334/14/183